HIV Seropositivity Clinical Trial
Official title:
Evaluation of Safety, Efficacy and Acceptability of the PrePexTM Device for Rapid Scale-up of Adult Male Circumcision Programs in Zimbabwe, Phase III PrePexTM Field Implementation Trial With HIV Positive Adult Males
Verified date | July 2017 |
Source | University of Washington |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will assess the safety of the PrePex device as applied to HIV positive men by assessing the rate of clinical adverse events. The study will include adult, HIV + men who are eligible to receive the PrePex procedure per the Zimbabwe Ministry of Health and Child Care (MOHCC) eligibility criteria.
Status | Completed |
Enrollment | 430 |
Est. completion date | May 2016 |
Est. primary completion date | February 2016 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Agrees to take an HIV test - HIV sero-positive - WHO HIV clinical stage 1 or 2 - Age 18 years and above - Agrees to be circumcised by PrePex - Able to understand the study procedures and requirements - Completes VMMC counseling - Agrees to return to the health care facility for follow-up visits or as instructed after this circumcision until complete healing 7 weeks from device application, or until cleared by a physician - Able to comprehend and freely give informed consent for study participation Exclusion Criteria: - Known bleeding/coagulation abnormality (excessive bleeding from nosebleeds, pulled tooth, or gums) - Uncontrolled diabetes (frequent treatment in a clinic or recent hospitalization for diabetes, frequent infections, hypertension, or kidney disease) - Active genital infection, anatomic abnormality or any other condition, which in the opinion of the investigator prevents the subject from undergoing circumcision using PrePex. - HIV sero-negative - HIV status unknown - WHO HIV stage 3 and above - Does not agree to PrePex |
Country | Name | City | State |
---|---|---|---|
Zimbabwe | Zengeza Clinic | Chitungwiza | Harare |
Lead Sponsor | Collaborator |
---|---|
University of Washington | Centers for Disease Control and Prevention, Ministry of Health and Child Care, Zimbabwe, University of Zimbabwe, Zimbabwe Community Health Intervention Research Project (ZiCHIRe), Zimbabwe |
Zimbabwe,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of adverse events among HIV+ males using PrePex device | The primary safety endpoint is the incidence of clinical adverse events and device-related incidents. Clinical related incidents such as the following: Site bleeding (bleeding that cannot be stopped with pressure of 30 seconds and requires suturing) Penis-wide diffuse hematoma Penis-wide diffuse edema Incision site infection and related symptoms Device-related incidents Necrotic Process not initiated Device does not remain in situ for the full 7 days (displacement) Note: This list of AEs is not exhaustive. Severity of AE will be determined according to PEPFAR/OGAC guidelines |
Device application through complete wound healing (up to 90 days) | |
Secondary | Pain assessment at key time points | Subject's subjective pain, tingling, and discomfort related to PrePex when applying the system, wearing it and removing it. This will be assessed by numeric pain, tingling and discomfort VAS scale (Pain = VAS x Duration in Minutes). Measured in the post placement recovery at 15 minutes after placement, and then 1, 2, and 3 hours post placement. As the necrotic process initiates, it is expected that some of subjects will have temporary discomfort during the first 2 hours after deployment (hence anaesthetic cream), which vanishes thereafter for the rest of the weeklong period when the device is in place. Some pain is expected for a short duration (about 10 seconds) when extracting the Inner Ring during the removal procedure. |
Placement through complete healing (up to 90 days) | |
Secondary | Abstinence until complete wound healing | Survival analysis of the timing of resumed sexual activity among subjects | Post placement through complete healing (up to 90 days) | |
Secondary | Factors associated with abstinence until complete wound healing | Patient factors (knowledge, attitudes) associated with abstinence from sex until wound healing is complete | Post placement through complete healing (approximately 90 days for men who participate in the qualitative component) | |
Secondary | Time to complete healing | Mean of days for complete healing (continuous measure) and factors associated with number of days to complete healing (continuous outcome - multiple linear regression) A completely healed circumcision as defined as, "Intact epithelium (unbroken skin) covering the epithelial as judged by the provider on visual inspection, meaning that none of the following are present: sutures, scabbing, drainage, moisture, gaps between epithelial edges or ulceration.] Optional validation by objective analysis of wounds by photographs |
Device placement through complete healing (up to 90 days) | |
Secondary | Cosmetic results | Objective analysis of photographs Glans fully exposed (complete circumcision) |
At complete healing (up to 90 days) | |
Secondary | Patient satisfaction | A composite measure created among patients involved in the qualitative component who will be asked about satisfaction with the PrePex™ MC procedure, barriers and motivators to uptake of VMMC through PrePex™, opinions around convenience of the device, tolerance of potential odour and whether participants would recommend PrePex™ MC to others. | 3 time points: Prior to the procedure, two weeks post-procedure, and 90 days post-procedure Device placement through ~90 days post procedure | |
Secondary | Patient daily life | Patients involved in the qualitative component will be asked about activities of daily living restrictions. They will complete a brief form that includes listing of activities of daily living, whether they are interrupted and for how long. This includes the average number of lost working hours (or potential working hours in unemployed). A composite measure will be created. | 3 time points: Prior to the procedure, two weeks post-procedure, and 90 days post-procedure Device placement through ~90 days post procedure | |
Secondary | PrePex staff perceptions | Responses by clinicians to Likert scale questions on their beliefs about PrePex VMMC and using this procedure on HIV+ men | 4 weeks after study implementation begins | |
Secondary | PrePex staff clinical skills | An overall assessment of clinician skills as a group will be made by combining and reporting on several indirect measures. Included measures will be the proportion of clients experiencing AEs and the average procedure time. • Assessing AE monitoring and reporting systems through completeness of reporting timeliness |
At study closing,approximately 18 months after study initiation | |
Secondary | PrePex AE monitoring and reporting systems | An ongoing assessment of AE monitoring and reporting systems through completeness of reporting timeliness of reports |
During all active follow-up: 90 days for participants | |
Secondary | PrePex staff perceptions of their clinical skills | Compilation report of Likert scale results from questions ascertaining PrepPex training, abilities, productivity and confidence. | 4 weeks after study implementation begins | |
Secondary | PrePex staff satisfaction | Compilation report on responses to likert scales question on their satisfaction performing PrePex on HIV+ men. | 4 weeks after study implementation begins |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03661203 -
Investigation of the Psychosocial Factors Responsible for the Late Recourse to HIV Testing Within MSM
|
||
Completed |
NCT00381212 -
A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05983536 -
The Evaluation of Anti-interference Ability and Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)
|
||
Recruiting |
NCT04832477 -
Assessing the PrEP Care Cascade Among Black Men and Transwomen in the Southeastern US
|
N/A | |
Active, not recruiting |
NCT04044586 -
HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, and Unsafe Injection Practices (12352 ANRS ROK INVEST)
|
||
Active, not recruiting |
NCT00797030 -
Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus
|
Phase 4 | |
Recruiting |
NCT04088916 -
Proviral DNA as a Target for HIV-1 Resistance Analysis
|
||
Completed |
NCT03367130 -
Improving Clinic Attendance for Medication Collection Among HIV Positive Individuals in Nepal
|
N/A | |
Completed |
NCT04849767 -
National Survey About Trajectory and Life Conditions of HIV Trans People in France
|
||
Completed |
NCT05674682 -
Seroincidence Study Among Men Who Have Sex With Men and Transgender Women - The ImPrEP Seroincidence Study
|
N/A | |
Recruiting |
NCT05174234 -
Precariousness and Sexual Vulnerability of People From Haiti Living With or Without HIV in French Guiana
|
||
Completed |
NCT00130819 -
Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants
|
Phase 2 | |
Active, not recruiting |
NCT04706624 -
Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics
|
N/A | |
Recruiting |
NCT03858478 -
Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France: Trial IMEA 055 - FAST
|
Phase 4 | |
Completed |
NCT02154971 -
Assessment of Age-related Hearing Loss in HIV-1 Patients
|
||
Recruiting |
NCT03333083 -
Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen
|
Phase 3 | |
Recruiting |
NCT03311945 -
Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM
|
Phase 3 | |
Recruiting |
NCT03795415 -
ANRS12373 GUNDO SO - Evaluation of an Empowerment Program for WLHIV in Mali
|
||
Completed |
NCT02003989 -
Revealing Increased Axonal Loss in Treated HIV Patients
|
N/A | |
Completed |
NCT01813292 -
Fluoride Metabolism, Bone Remodelling and Mineral Density in HIV Patients Treated With Tenofovir +/- Emtricitabine
|
N/A |